

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-149) VOFATAMAB

PRONUNCIATION voe fat' a mab

THERAPEUTIC CLAIM Treatment of relapsed or refractory advanced urothelial cell carcinoma (UCC)

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human fibroblast growth factor receptor type 3) (human monoclonal MFGR1877S heavy chain), disulfide with human monoclonal MFGR1877S κ -chain, dimer
2. immunoglobulin G1-kappa, anti-(*Homo sapiens* Fibroblast growth factor receptor 3 (FGFR-3, antigen CD333)); humanized monoclonal antibody; γ 1 heavy chain (1-457) [*Homo sapiens* VH (IGHV3-66*01 (86%) –(IGHD)-IGHJ4*01) [8.8.20] (1-127) -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(224)]} (128-457)] (230-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-5*01 (87%) –IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (236-236":239-239")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFT	STGISWVRQA	PGKGLEWVGR	50
IYPTSGSTNY	ADSVKGRFTI	SADTSKNTAY	LQMNSLRAED	TAVYYCARTY	100
GIYDLYVDYT	EYVMDYWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	150
ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVTVVPS	200
SSLGTQTYIC	NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	250
FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	300
PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	350
GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	400
YKTTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNYHTQKS	450
LSSLSPGK					457

Light chain

DIQMTQSPSS	LSASVGDRV	ITCRASQD	TSLAWYKQKP	GKAPKLLIYS	50'
ASFLYSGVPS	RFSGSGSGTD	FRTLTISLQ	EDFATYYCQQ	STGHPQTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"	154-210	154"-210"
214'-230	214"-230"	236-236"	239-239"	271-331	271"-331"	377-435	377"-435"

Glycosylation sites (N)

Asn-307 Asn-307"

MOLECULAR FORMULA C₆₄₉₆H₁₀₀₄₀N₁₇₁₆O₂₀₅₀S₄₄ (non-glycosylated)

MOLECULAR WEIGHT 146.4 kDa (non-glycosylated)

TRADEMARK None as yet

SPONSOR	BioClin Therapeutics, Inc.
CODE DESIGNATIONS	B-701, Anti-FGR3, MFGR1877S, MFGR1877A
<u>CAS</u> REGISTRY NUMBER	1312305-12-6
UNII	JMH6YR91PG
WHO NUMBER	10919

gbk